When does takhzyro lose exclusivity?

When does Takhzyro’s market exclusivity run out?

Takhzyro (lanadelumab) is protected by patents that can delay generic or biosimilar competition after approval. The exact date when “exclusivity” ends depends on which protection you mean—patent expiration vs. regulatory exclusivity (if any)—and on the country.

DrugPatentWatch tracks related patent activity for Takhzyro and is the most direct place to check the latest expiration timeline for specific jurisdictions: DrugPatentWatch: Takhzyro (lanadelumab) [1]

What kind of exclusivity usually matters for a drug like Takhzyro?

For biologics such as lanadelumab, the end of exclusivity is often driven mainly by:
- Patent expiration on the drug product, method, or formulation
- Patent litigation or settlements that can extend the effective time before competitors enter

Those details are jurisdiction-specific and can shift as patent estates change or cases progress, which is why the most reliable way to pin down the date is to look up the specific patent set and the country’s rules on exclusivity [1].

How can you check the exact exclusivity-loss date you care about?

If you tell me the country (for example, US or EU) and whether you mean “patent expiration” or “regulatory exclusivity,” I can narrow the answer to the relevant protections using the Takhzyro patent record. The same DrugPatentWatch page used above is where you’d start for the date-specific breakdown [1].

Sources:
[1] https://www.drugpatentwatch.com/